A. Kamiunten

发表

Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator.

A. Iwama, K. Nagata, K. Aoyama, 2015, Blood.

MYELOID NEOPLASIA Loss of TET 2 has dual roles in murine myeloproliferative neoplasms : disease sustainer and disease accelerator

A. Iwama, K. Nagata, K. Aoyama, 2014 .

TET2 is essential for survival and hematopoietic stem cell homeostasis

A. Iwama, K. Nagata, K. Shimoda, 2012, Leukemia.

Mice with Calr mutations homologous to human CALR mutations only exhibit mild thrombocytosis

M. Ikawa, K. Nagata, K. Shimoda, 2019, Blood Cancer Journal.

Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib

K. Nagata, A. Sawaguchi, K. Shimoda, 2016, Leukemia.

Elevated HIF-1α expression of acute myelogenous leukemia stem cells in the endosteal hypoxic zone may be a cause of minimal residual disease in bone marrow after chemotherapy.

H. Ohnishi, T. Matsunaga, H. Dobashi, 2012, Leukemia research.

Gene expression profiling of loss of TET2 and/or JAK2V617F mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasms

A. Iwama, K. Nagata, K. Aoyama, 2015, Genomics data.

Real-World Data on Clinical Features, Outcomes, and Prognostic Factors in Multiple Myeloma from Miyazaki Prefecture, Japan

K. Shimoda, H. Kawano, M. Sekine, 2020, Journal of clinical medicine.

CD3 and EBER double positive cells in bone marrow are a diagnostic aid for EBV-positive T-cell lymphoproliferative disorders of childhood

K. Nagata, K. Shimoda, Shojiro Yamamoto, 2012, International Cancer Conference Journal.

Loss of Tyrosine Kinase 2 Does Not Affect the Severity of Jak2V617F-induced Murine Myeloproliferative Neoplasm.

K. Nagata, K. Shimoda, T. Miike, 2017, Anticancer research.

Potentiated activation of VLA-4 and VLA-5 accelerates proplatelet-like formation

S. Bandoh, Kensuke Matsumoto, T. Matsunaga, 2012, Annals of Hematology.

CARD11 mutation and HBZ expression induce lymphoproliferative disease and adult T-cell leukemia/lymphoma

S. Ogawa, T. Matsuda, T. Ohshima, 2022, Communications Biology.

TP53 and PTEN mutations were shared in concurrent germ cell tumor and acute megakaryoblastic leukemia

K. Shimoda, Yuichiro Sato, H. Kataoka, 2019, BMC Cancer.

Acute myeloid leukemia in clinical practice: a retrospective population-based cohort study in Miyazaki Prefecture, Japan

H. Moritake, T. Matsunaga, K. Shimoda, 2012, International Journal of Hematology.

Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan

K. Shimoda, H. Kawano, Masafumi Ito, 2018, International Journal of Hematology.

TET2 mutation in diffuse large B-cell lymphoma.

K. Nagata, K. Shimoda, T. Miike, 2017, Journal of clinical and experimental hematopathology : JCEH.

TET2 Mutation in Adult T-Cell Leukemia/Lymphoma.

K. Nagata, K. Shimoda, T. Miike, 2015, Journal of clinical and experimental hematopathology : JCEH.

Calreticulin haploinsufficiency augments stem cell activity and is required for onset of myeloproliferative neoplasms.

K. Nagata, M. Ono, K. Ikeda, 2020, Blood.

Whole-genome landscape of adult T-cell leukemia/lymphoma.

S. Miyano, T. Shibata, Y. Shiraishi, 2021, Blood.

Single-Cell Analysis of the Multicellular Ecosystem in Viral Carcinogenesis by HTLV-1

S. Ogawa, A. Utsunomiya, K. Shimoda, 2021, Blood cancer discovery.

Nasopharyngeal carcinoma with bone marrow metastasis: positive response to weekly paclitaxel chemotherapy.

Yoshiko Umekita, K. Shimoda, T. Kawabata, 2015, Internal medicine.

Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice

K. Nagata, A. Sawaguchi, K. Shimoda, 2020, Leukemia.

Higher average chemotherapy dose intensity improves prognosis in patients with aggressive adult T‐cell leukemia/lymphoma

K. Shimoda, H. Kawano, M. Sekine, 2020, European journal of haematology.

Outcome of allogeneic hematopoietic cell transplantation in patients with adult T‐cell leukemia

K. Shimoda, Koji Kato, M. Sekine, 2018, Hematological oncology.

Effects of mogamulizumab in adult T‐cell leukemia/lymphoma in clinical practice

K. Shimoda, H. Kawano, M. Sekine, 2017, European journal of haematology.

Early/prefibrotic primary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia

K. Shimoda, H. Kawano, Masafumi Ito, 2018, International Journal of Hematology.

TET 2 mutation in diffuse large B-cell lymphoma

K. Nagata, K. Shimoda, T. Miike, 2017 .

Monocyte-derived fibrocytes elimination had little contribution on liver fibrosis.

K. Nagata, A. Sawaguchi, K. Shimoda, 2019, Hepatobiliary & pancreatic diseases international : HBPD INT.

Prognosis of Indolent Adult T-Cell Leukemia/Lymphoma

K. Shimoda, H. Kawano, M. Sekine, 2022, Viruses.

Primary central nervous system lymphoma in Miyazaki, southwestern Japan, a human T-lymphotropic virus Type-1 (HTLV-1)-endemic area: clinicopathological review of 31 cases.

H. Takeshima, Y. Asada, K. Shimoda, 2014, Journal of clinical and experimental hematopathology : JCEH.

Mice with Calr mutations homologous to human CALR mutations only exhibit mild thrombocytosis

M. Ikawa, K. Nagata, K. Shimoda, 2019, Blood Cancer Journal.

Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With JAK2- or CALR-Mutations

K. Nagata, K. Shimoda, T. Miike, 2016, Annals of laboratory medicine.